JP2017514800A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514800A5
JP2017514800A5 JP2016560809A JP2016560809A JP2017514800A5 JP 2017514800 A5 JP2017514800 A5 JP 2017514800A5 JP 2016560809 A JP2016560809 A JP 2016560809A JP 2016560809 A JP2016560809 A JP 2016560809A JP 2017514800 A5 JP2017514800 A5 JP 2017514800A5
Authority
JP
Japan
Prior art keywords
molecule
composition
polypeptide
nucleic acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560809A
Other languages
English (en)
Japanese (ja)
Other versions
JP6728056B2 (ja
JP2017514800A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/024400 external-priority patent/WO2015154059A2/en
Publication of JP2017514800A publication Critical patent/JP2017514800A/ja
Publication of JP2017514800A5 publication Critical patent/JP2017514800A5/ja
Application granted granted Critical
Publication of JP6728056B2 publication Critical patent/JP6728056B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560809A 2014-04-04 2015-04-04 Her3標的ナノ粒子によりトラスツズマブ耐性her2+乳癌を標的にすること Expired - Fee Related JP6728056B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461975687P 2014-04-04 2014-04-04
US61/975,687 2014-04-04
PCT/US2015/024400 WO2015154059A2 (en) 2014-04-04 2015-04-04 Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020114165A Division JP2020176123A (ja) 2014-04-04 2020-07-01 Her3標的ナノ粒子によりトラスツズマブ耐性her2+乳癌を標的にすること

Publications (3)

Publication Number Publication Date
JP2017514800A JP2017514800A (ja) 2017-06-08
JP2017514800A5 true JP2017514800A5 (cg-RX-API-DMAC7.html) 2018-05-17
JP6728056B2 JP6728056B2 (ja) 2020-07-22

Family

ID=54241451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016560809A Expired - Fee Related JP6728056B2 (ja) 2014-04-04 2015-04-04 Her3標的ナノ粒子によりトラスツズマブ耐性her2+乳癌を標的にすること
JP2020114165A Pending JP2020176123A (ja) 2014-04-04 2020-07-01 Her3標的ナノ粒子によりトラスツズマブ耐性her2+乳癌を標的にすること

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020114165A Pending JP2020176123A (ja) 2014-04-04 2020-07-01 Her3標的ナノ粒子によりトラスツズマブ耐性her2+乳癌を標的にすること

Country Status (13)

Country Link
US (2) US9850293B2 (cg-RX-API-DMAC7.html)
EP (1) EP3129066B1 (cg-RX-API-DMAC7.html)
JP (2) JP6728056B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160141751A (cg-RX-API-DMAC7.html)
CN (1) CN106170305A (cg-RX-API-DMAC7.html)
AU (1) AU2015240460A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016023025A2 (cg-RX-API-DMAC7.html)
CA (1) CA2943297A1 (cg-RX-API-DMAC7.html)
IL (1) IL248046B (cg-RX-API-DMAC7.html)
MX (1) MX2016013025A (cg-RX-API-DMAC7.html)
RU (1) RU2692104C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015154059A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201607375B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078927B2 (en) * 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
MX366347B (es) 2012-08-03 2019-07-05 Cedars Sinai Medical Center Aislamiento de mutantes mejoradores del trafico de la proteina de administracion de farmaco.
AU2014262653B2 (en) 2013-05-08 2018-07-26 Cedars-Sinai Medical Center Targeting corroles for tumor toxicity and MRI
EP3791889B1 (en) 2014-01-17 2024-02-21 Cedars-Sinai Medical Center C-met receptor targeting constructs and uses thereof
JP6728056B2 (ja) 2014-04-04 2020-07-22 シーダーズ—シナイ メディカル センター Her3標的ナノ粒子によりトラスツズマブ耐性her2+乳癌を標的にすること
AU2017271662A1 (en) * 2016-05-27 2018-12-06 Cedars-Sinai Medical Center Drug-delivery nanoparticles and treatments for drug-resistant cancer
CN106474472B (zh) * 2016-10-11 2021-06-08 连云港市第一人民医院 肿瘤曲妥珠单抗靶向anti-miR-21纳米粒子及其制备方法
CA3087325A1 (en) * 2018-01-02 2019-07-11 Cedars-Sinai Medical Center Nanoparticles for the targeted delivery of therapeutic polypeptides
CN113950337A (zh) * 2019-01-03 2022-01-18 金圣千 利用pH依赖性细胞膜穿透肽的药物载体以及所述药物载体与药物的复合体
KR102182985B1 (ko) * 2019-01-03 2020-11-26 주식회사 바이오이즈 pH 의존적 막 투과성 펩타이드를 이용한 약물 운반체 및 그것과 약물의 복합체
CN115776908A (zh) * 2020-05-12 2023-03-10 拉什大学医学中心 用于治疗癌症的组合物和方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US6855135B2 (en) 2000-11-29 2005-02-15 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US20030170826A1 (en) 2001-02-02 2003-09-11 Peter Rabinovich Peptides for facilitating composite receptor expression and translocation of macromolecules
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
EP1374812A1 (en) 2002-06-28 2004-01-02 Biopol Co., Ltd. Multilayered microporous foam dressing and method for manufacturing the same
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
TWI355894B (en) 2003-12-19 2012-01-11 Du Pont Herbicidal pyrimidines
US20060014712A1 (en) 2004-05-30 2006-01-19 Cemines, Inc. Controlled delivery of therapeutic compounds
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20110052697A1 (en) 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
EP2473160A4 (en) 2009-09-01 2015-06-03 Univ Northwestern ADMINISTRATION OF THERAPEUTIC AGENTS WITH OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS SUPPORT
WO2011094335A2 (en) * 2010-01-26 2011-08-04 Yale University Microrna signatures predicting responsiveness to anti-her2 therapy
MX2014014266A (es) 2012-05-22 2015-06-23 Smith & Nephew Aparatos y metodos para terapia de heridas.
MX366347B (es) 2012-08-03 2019-07-05 Cedars Sinai Medical Center Aislamiento de mutantes mejoradores del trafico de la proteina de administracion de farmaco.
AU2014262653B2 (en) 2013-05-08 2018-07-26 Cedars-Sinai Medical Center Targeting corroles for tumor toxicity and MRI
EP3791889B1 (en) 2014-01-17 2024-02-21 Cedars-Sinai Medical Center C-met receptor targeting constructs and uses thereof
JP6728056B2 (ja) 2014-04-04 2020-07-22 シーダーズ—シナイ メディカル センター Her3標的ナノ粒子によりトラスツズマブ耐性her2+乳癌を標的にすること
BR112017003986A2 (pt) 2014-08-27 2018-02-27 Peptimed Inc composições e métodos anti-tumor

Similar Documents

Publication Publication Date Title
JP2017514800A5 (cg-RX-API-DMAC7.html)
Araste et al. Peptide-based targeted therapeutics: Focus on cancer treatment
JP2016535009A5 (cg-RX-API-DMAC7.html)
JP2019527706A5 (cg-RX-API-DMAC7.html)
EP4335511A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
JP2018529656A5 (cg-RX-API-DMAC7.html)
TR201906470T4 (tr) İmmünomodülatörler.
JP2008502584A5 (cg-RX-API-DMAC7.html)
JP2019526578A5 (cg-RX-API-DMAC7.html)
JP2008507536A5 (cg-RX-API-DMAC7.html)
Izar et al. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer
WO2012094653A4 (en) Compositions and methods for macromolecular drug delivery
JP2017533920A5 (cg-RX-API-DMAC7.html)
JP2019506862A5 (cg-RX-API-DMAC7.html)
JP2013166763A5 (cg-RX-API-DMAC7.html)
JP2021502980A5 (cg-RX-API-DMAC7.html)
JP2015512398A5 (cg-RX-API-DMAC7.html)
JP2016530233A5 (cg-RX-API-DMAC7.html)
JP2015514756A5 (cg-RX-API-DMAC7.html)
JP2016526021A5 (cg-RX-API-DMAC7.html)
JP2010523696A5 (cg-RX-API-DMAC7.html)
JP2016116527A5 (cg-RX-API-DMAC7.html)
EA201892797A1 (ru) Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака
WO2015154059A3 (en) Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
HK1215193A1 (zh) 用dll4拮抗剂治疗卵巢癌的方法